[Eileenk]

New study re: Ninlaro in high-risk multiple myeloma

by Eileenk on Fri Nov 17, 2017 10:37 am

Hi folks,

I just came across this article with some positive clinical trial results for Ninlaro (ixazomib) and wanted to share.

Have a great day!
Eileen

Article citation:

Avet-Loiseau, H, et al,"Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients," Blood, Oct 20, 2017(abstract)

Article abstract:

Certain cytogenetic abnormalities are known to adversely impact outcomes in patients with multiple myeloma (multiple myeloma). The phase 3 TOURMALINE-MM1 study demonstrated a signif­icant im­prove­ment in progression-free survival (PFS) with ixazomib-lenalidomide-dexamethasone (IRd) com­pared with placebo-Rd. This pre-planned analysis assessed the efficacy and safety of IRd versus placebo-Rd according to cyto­genetic risk, as assessed using fluorescence in-situ hybridi­zation. High-risk cyto­genetic abnormalities were defined as del(17p), t(4;14), and/or t(14;16); additionally, patients were assessed for 1q21 ampli­fi­ca­tion. Of 722 randomized patients, 552 had cyto­genetic results; 137 (25%) had high-risk cyto­genetic abnormalities and 172 (32%) had 1q21 amplification alone. PFS was improved with IRd versus placebo-Rd in both high-risk and standard-risk cyto­genetics subgroups: in high-risk patients, hazard ratio (HR) was 0.543 (95% confidence interval [CI], 0.321-0.918; p = .021), with median PFS of 21.4 versus 9.7 months; in standard-risk patients, HR was 0.640 (95% CI, 0.462-0.888; p = .007), with median PFS of 20.6 versus 15.6 months. This PFS benefit was con­sistent across subgroups with individual high-risk cyto­genetic abnormalities, includ­ing patients with del(17p) (HR 0.596; 95% CI, 0.286-1.243). PFS was also longer with IRd versus placebo-Rd in patients with 1q21 amplification (HR 0.781; 95% CI, 0.492-1.240), and in the "expanded high-risk" group, defined as those with high-risk cyto­genetic ab­nor­malities and/or 1q21 ampli­fication (HR 0.664; 95% CI, 0.474-0.928). IRd demonstrated substantial benefit compared with placebo-Rd in RRMM patients with high-risk and standard-risk cyto­genetics, and im­proves the poor PFS associated with high-risk cyto­genetic abnormalities. This trial was registered at ClinicalTrials.gov as NCT01564537.